17-ethyl-5-(2,2,2-trifluoroethoxy)-14-oxa-2,4,6,8,17,20,29-heptazatetracyclo[20.2.2.210,13.13,7]nonacosa-1(24),3,5,7(29),10(28),11,13(27),22,25-nonaen-21-one | 1287219-80-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: 17-ethyl-5-(2,2,2-trifluoroethoxy)-14-oxa-2,4,6,8,17,20,29-heptazatetracyclo[20.2.2.210,13.13,7]nonacosa-1(24),3,5,7(29),10(28),11,13(27),22,25-nonaen-21-one
• CAS: 1287219-80-0
• 化学式: C₂₅H₂₈F₃N₇O₃
• 分子量: 531.538
• InChiKey: IQANUXXHODUGLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  38
• 可旋转键数：
  3
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  12

文献信息

• Compounds for the Treatment of Hepatitis C
  申请人：Wang Tao

  公开号：US20110086858A1

  公开（公告）日：2011-04-14

  The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

  该披露提供了公式I的化合物，包括药用可接受的盐，以及使用这些化合物的组合物和方法。这些化合物具有抗丙型肝炎病毒（HCV）的活性，并可能对感染HCV的患者有用。
• [EN] COMPOUNDS FOR THE TREATMENT OF HEPATITIS C<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011047119A1

  公开（公告）日：2011-04-21

  The disclosure provides compounds of formula (I), including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.